A clinical trial found that nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy. The results of the trials were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23. Antiangiogenic drugs are anticancer drugs designed to cut off the blood supply that brings tumors the nutrients they need ...You have just read an article categorized health
titled Resistance to Certain Anticancer Drugs? New Nanopharmaceutical may Come In Handy.
Written by:
editor - Monday, October 28, 2013
There are currently no comments for "Resistance to Certain Anticancer Drugs? New Nanopharmaceutical may Come In Handy"
Post a Comment